Ankylosing spondylitis: From cells to genes

International Journal of Inflammation

Volumn 2013, Issue , 2013, Pages

  Zambrano Zaragoza, José Francisco ^a   Agraz Cibrian, Juan Manuel ^a   González Reyes, Christian ^a   Durán Avelar, Ma De Jesús ^a   Vibanco Pérez, Norberto ^a  

^a UNIVERSIDAD AUTÓNOMA DE NAYARIT   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; AMINOPEPTIDASE; BISPHOSPHONIC ACID DERIVATIVE; CHEMOKINE RECEPTOR CCR6; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; ENDOPLASMIC RETICULUM AMINOPEPTIDASE 1; ETANERCEPT; FC RECEPTOR; HLA B27 ANTIGEN; INFLIXIMAB; INTERLEUKIN 17; PROGRAMMED DEATH 1 RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG;

ANKYLOSING SPONDYLITIS; ARTICLE; AUTOIMMUNE DISEASE; CCR6 GENE; CTLA 4 GENE; DRUG POTENTIATION; ERAP1 GENE; FC GAMMA R GENE; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SUSCEPTIBILITY; HUMAN; IMMUNE RESPONSE; MOLECULAR PATHOLOGY; NATURAL KILLER CELL; PATHOGENESIS; PD 1 GENE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SINGLE NUCLEOTIDE POLYMORPHISM; TH17 CELL; TNFA GENE;

EID: 84881425712     PISSN: 20908040     EISSN: 20420099     Source Type: Journal    
DOI: 10.1155/2013/501653     Document Type: Article

References (187)

1. Ehrenfeld M., Spondyloarthropathies. Best Practice and Research: Clinical Rheumatology 2012 26 1 135 145 2-s2.0-84858401535 10.1016/j.berh.2012.01.002
2. Braun J., Sieper J., Ankylosing spondylitis. Lancet 2007 369 9570 1379 1390 2-s2.0-34247164611 10.1016/S0140-6736(07)60635-7 (Pubitemid 46590387)
3. Ebringer A., Wilson C., HLA molecules, bacteria and autoimmunity. Journal of Medical Microbiology 2000 49 4 305 311 2-s2.0-0012964271 (Pubitemid 30189463)
4. Feldtkeller E., Khan M. A., van der Heijde D., van der Linden S., Braun J., Age at disease onset and diagnosis delay in HLA-B27 negative vs. positive patients with ankylosing spondylitis. Rheumatology International 2003 23 2 61 66 2-s2.0-0037356696 (Pubitemid 36384722)
5. van der Linden S., Valkenburg H. A., Cats A., Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis and Rheumatism 1984 27 4 361 368 2-s2.0-0021272107 (Pubitemid 14134775)
6. Brown M. A., Breakthroughs in genetic studies of ankylosing spondylitis. Rheumatology 2008 47 2 132 137 2-s2.0-38649113910 10.1093/rheumatology/kem269 (Pubitemid 351168219)
7. Brewerton D. A., Hart F. D., Nicholls A., Caffrey M., James D. C., Sturrock R. D., Ankylosing spondylitis and HL-A 27. Lancet 1973 1 7809 904 907 2-s2.0-0015938046
8. Schlosstein L., Terasaki P. I., Bluestone R., Pearson C. M., High association of an HL-A antigen, W27, with ankylosing spondylitis. New England Journal of Medicine 1973 288 14 704 706 2-s2.0-0015914854
9. Reveille J. D., Arnett F. C., Spondyloarthritis: update on pathogenesis and management. American Journal of Medicine 2005 118 6 592 603 2-s2.0-19544368444 10.1016/j.amjmed.2005.01.001 (Pubitemid 40732696)
10. van der Linden S. M., Valkenburg H. A., de Jongh B. M., Cats A., The risk of developing ankylosing spondylitis in HLA-B27 positive individuals. A comparison of relatives of spondylitis patients with the general population. Arthritis and Rheumatism 1984 27 3 241 249 2-s2.0-0021347628 (Pubitemid 14163215)
11. Brown M. A., Pile K. D., Kennedy L. G., Calin A., Darke C., Bell J., Wordsworth B. P., Cornélis F., HLA class I associations of ankylosing spondylitis in the white population in the United Kingdom. Annals of the Rheumatic Diseases 1996 55 4 268 270 2-s2.0-0029879899 (Pubitemid 26120706)
12. Reveille J. D., Major histocompatibility genes and ankylosing spondylitis. Best Practice and Research: Clinical Rheumatology 2006 20 3 601 609 2-s2.0-33745045027 10.1016/j.berh.2006.03.004 (Pubitemid 43869449)
13. Gran J. T., Husby G., Hordvik M., Prevalence of ankylosing spondylitis in males and females in a young middle-aged population of Tromso, northern Norway. Annals of the Rheumatic Diseases 1985 44 6 359 367 2-s2.0-0021825105 (Pubitemid 15053515)
14. Braun J., Bollow M., Remlinger G., Eggens U., Rudwaleit M., Distler A., Sieper J., Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors. Arthritis and Rheumatism 1998 41 1 58 67 (Pubitemid 28041923)
15. Reveille J. D., Ball E. J., Khan M. A., HLA-B27 and genetic predisposing factors in spondyloarthropathies. Current Opinion in Rheumatology 2001 13 4 265 272 2-s2.0-0034853747 10.1097/00002281-200107000-00004 (Pubitemid 32831816)
16. Brown M. A., Wordsworth B. P., Reveille J. D., Genetics of ankylosing spondylitis. Clinical and Experimental Rheumatology 2002 20 6, supplement 28 S43 S49 2-s2.0-0036399587
17. Armas J. B., Gonzalez S., Martinez-Borra J., Laranjeira F., Ribeiro E., Correia J., Ferreira M. L., Toste M., López-Vazquez A., López-Larrea C., Susceptibility to ankylosing spondylitis is independent of the Bw4 and Bw6 epitopes of HLA-B27 alleles. Tissue Antigens 1999 53 3 237 243 2-s2.0-0033024247 10.1034/j.1399-0039.1999.530303.x (Pubitemid 29121826)
18. MacLean I. L., Iqball S., Woo P., Keat A. C. S., Hughes R. A., Kingsley G. H., Knight S. C., HLA-B27 subtypes in the spondarthropathies. Clinical and Experimental Immunology 1993 91 2 214 219 2-s2.0-0027394565 (Pubitemid 23045664)
19. López-Larrea C., Gonzalez-Roces S., Alvarez V., HLA-B27 structure, function, and disease association. Current Opinion in Rheumatology 1996 8 4 296 308 2-s2.0-0029737948 (Pubitemid 26299807)
20. Ball E. J., Khan M. A., HLA-B27 polymorphism. Joint Bone Spine 2001 68 5 378 382 2-s2.0-0034769308 10.1016/S1297-319X(01)00294-9 (Pubitemid 32988523)
21. D'Amato M., Fiorillo M. T., Carcassi C., Mathieu A., Zuccarelli A., Bitti P. P., Tosi R., Sorrentino R., Relevance of residue 116 of HLA-B27 in determining susceptibility to ankylosing spondylitis. European Journal of Immunology 1995 25 11 3199 3201 2-s2.0-0028839838 10.1002/eji.1830251133
22. Paladini F., Taccari E., Fiorillo M. T., Cauli A., Passiu G., Mathieu A., Punzi L., Lapadula G., Scarpa R., Sorrentino R., Distribution of HLA-B27 subtypes in Sardinia and continental Italy and their association with spondylarthropathies. Arthritis and Rheumatism 2005 52 10 3319 3321 2-s2.0-26844522808 10.1002/art.21308 (Pubitemid 41447118)
23. Nurzia E., Narzi D., Cauli A., Mathieu A., Tedeschi V., Caristi S., Sorrentino R., Böckmann R. A., Fiorillo M. T., Interaction pattern of Arg 62 in the a-pocket of differentially disease-associated HLA-B27 subtypes suggests distinct TCR binding modes. PLoS ONE 2012 7 3 2-s2.0-84857759560 10.1371/journal.pone.0032865 e32865
24. Smith J. A., Märker-Hermann E., Colbert R. A., Pathogenesis of ankylosing spondylitis: current concepts. Best Practice and Research: Clinical Rheumatology 2006 20 3 571 591 2-s2.0-33746897749 10.1016/j.berh.2006.03.001 (Pubitemid 44182767)
25. Ziegler A., Loll B., Misselwitz R., Uchanska-Ziegler B., Implications of structural and thermodynamic studies of HLA-B27 subtypes exhibiting differential association with ankylosing spondylitis. Advances in Experimental Medicine and Biology 2009 649 177 194 2-s2.0-70349567381 10.1007/978-1-4419-0298-6-13
26. Bird L. A., Peh C. A., Kollnbeger S., Elliott T., McMichael A.J. A. J., Bowness P., Lymphoblastoid cells express HLA-B27 homodimers both intracellularly and at the cell surface following endosomal recycling. European Journal of Immunology 2003 33 3 748 759 2-s2.0-0037352755 10.1002/eji.200323678 (Pubitemid 36367678)
27. Kollnberger S., Bird L., Sun M. Y., Retiere C., Braud V. M., McMichael A., Bowness P., Cell-surface expression and immune receptor recognition of HLA-B27 homodimers. Arthritis and Rheumatism 2002 46 11 2972 2982 2-s2.0-0036846149 10.1002/art.10605 (Pubitemid 35315891)
28. Allen R. L., Trowsdale J., Recognition of classical and heavy chain forms of HLA-B27 by leukocyte receptors. Current Molecular Medicine 2004 4 1 59 65 2-s2.0-1442326724 10.2174/1566524043479329 (Pubitemid 38279432)
29. Chan A. T., Kollnberger S. D., Wedderburn L. R., Bowness P., Expansion and enhanced survival of natural killer cells expressing the killer immunoglobulin-like receptor KIR3DL2 in spondylarthritis. Arthritis and Rheumatism 2005 52 11 3586 3595 2-s2.0-27744513659 10.1002/art.21395 (Pubitemid 41612228)
30. Marcilla M., López de Castro J. A., Peptides: The cornerstone of HLA-B27 biology and pathogenetic role in spondyloarthritis. Tissue Antigens 2008 71 6 495 506 2-s2.0-43849110108 10.1111/j.1399-0039.2008.01051.x (Pubitemid 351697253)
31. Vázquez M. N., López de Castro J. A., Similar cell surface expression of β 2-microglobulin-free heavy chains by HLA-B27 subtypes differentially associated with ankylosing spondylitis. Arthritis and Rheumatism 2005 52 10 3290 3299 2-s2.0-26844446015 10.1002/art.21284 (Pubitemid 41447112)
32. Thomas G. P., Brown M. A., Genetics and genomics of ankylosing spondylitis. Immunological Reviews 2010 233 1 162 180 2-s2.0-73249129708 10.1111/j.0105-2896.2009.00852.x
33. Mear J. P., Schreiber K. L., Münz C., Zhu X., Stevanović S., Rammensee H. G., Rowland-Jones S. L., Colbert R. A., Misfolding of HLA-B27 as a result of its B pocket suggests a novel mechanism for its role in susceptibility to spondyloarthropathies. Journal of Immunology 1999 163 12 6665 6670 2-s2.0-0032742012
34. DeLay M. L., Turner M. J., Klenk E. I., Smith J. A., Sowders D. P., Colbert R. A., HLA-B27 misfolding and the unfolded protein response augment interleukin-23 production and are associated with Th17 activation in transgenic rats. Arthritis and Rheumatism 2009 60 9 2633 2643 2-s2.0-69449086287 10.1002/art.24763
35. Colbert R. A., DeLay M. L., Layh-Schmitt G., Sowders D. P., HLA-B27 misfolding and spondyloarthropathies. Prion 2009 3 1 15 26 2-s2.0-66749147160 10.4161/pri.3.1.8072
36. Pahl H. L., Baeuerle P. A., The ER overload response: activation of NF- B. Trends in Biochemical Sciences 1997 22 2 63 67 2-s2.0-0031081340 10.1016/S0968-0004(96)10073-6 (Pubitemid 27076808)
37. Virtala M., Kirveskari J., Granfors K., HLA-B27 modulates the survival of Salmonella enteritidis in transfected L cells, possibly by impaired nitric oxide production. Infection and Immunity 1997 65 10 4236 4242 2-s2.0-0030798758 (Pubitemid 27422083)
38. Jiang Y., Zhang R., Zheng J., Liu P., Tang G., Lv H., Zhang L., Shang Z., Zhan Y., Lv W., Shi M., Zhang R., Meta-analysis of 125 rheumatoid arthritis-related single nucleotide polymorphisms studied in the past two decades. PloS One 2012 7 12 10.1371/journal.pone.0051571 e51571
39. Mathieu A., Paladini F., Vacca A., Cauli A., Fiorillo M. T., Sorrentino R., The interplay between the geographic distribution of HLA-B27 alleles and their role in infectious and autoimmune diseases: a unifying hypothesis. Autoimmunity Reviews 2009 8 5 420 425 2-s2.0-61549109883 10.1016/j.autrev.2009. 01.003
40. Miossec P., Kolls J. K., Targeting IL-17 and TH17 cells in chronic inflammation. Nature Reviews Drug Discovery 2012 11 10 763 776
41. Yeremenko N., Baeten D., IL-17 in spondyloarthritis: is the T-party over? Arthritis Research and Therapy 2011 13 3, article 115 2-s2.0-79959625184 10.1186/ar3351
42. Taylan A., Sari I., Kozaci D. L., Yuksel A., Bilge S., Yildiz Y., Sop G., Coker I., Gunay N., Akkoc N., Evaluation of the T helper 17 axis in ankylosing spondylitis. Rheumatology International 2012 32 8 2511 2515 2-s2.0-79960467549 10.1007/s00296-011-1995-7
43. Shen H., Goodall J. C., Hill Gaston J. S., Frequency and phenotype of peripheral blood Th17 cells in ankylosing spondylitis and rheumatoid arthritis. Arthritis and Rheumatism 2009 60 6 1647 1656 2-s2.0-66449133523 10.1002/art.24568
44. Di Cesare A., Di Meglio P., Nestle F. O., The IL-23Th17 axis in the immunopathogenesis of psoriasis. Journal of Investigative Dermatology 2009 129 6 1339 1350 2-s2.0-67349230808 10.1038/jid.2009.59
45. Ahern P. P., Izcue A., Maloy K. J., Powrie F., The interleukin-23 axis in intestinal inflammation. Immunological Reviews 2008 226 1 147 159 2-s2.0-55149112367 10.1111/j.1600-065X.2008.00705.x
46. Limón-Camacho L., Vargas-Rojas M. I., Vázquez-Mellado J., Casasola-Vargas J., Moctezuma J. F., Burgos-Vargas R., Llorente L., In vivo peripheral blood proinflammatory T cells in patients with ankylosing spondylitis. Journal of Rheumatology 2012 39 4 830 835 2-s2.0-84859455038 10.3899/jrheum.110862
47. Harrington L. E., Hatton R. D., Mangan P. R., Turner H., Murphy T. L., Murphy K. M., Weaver C. T., Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nature Immunology 2005 6 11 1123 1132 2-s2.0-27544490377 10.1038/ni1254 (Pubitemid 41541790)
48. Iwakura Y., Ishigame H., The IL-23/IL-17 axis in inflammation. Journal of Clinical Investigation 2006 116 5 1218 1222 2-s2.0-33646417072 10.1172/JCI28508
49. Noordenbos T., Yeremenko N., Gofita I., van de Sande M., Tak P. P., Caňete J. D., Baeten D., Interleukin-17-positive mast cells contribute to synovial inflammation in spondylarthritis. Arthritis and Rheumatism 2012 64 1 99 109 2-s2.0-84855291352 10.1002/art.33396
50. Zhang L., Li Y. G., Li Y. H., Qi L., Liu X. G., Yuan C. Z., Hu N. W., Ma D. X., Li Z. F., Yang Q., Li W., Li J. M., Increased frequencies of th22 cells as well as th17 cells in the peripheral blood of patients with ankylosing spondylitis and rheumatoid arthritis. PLoS ONE 2012 7 4 2-s2.0-84859237495 10.1371/journal.pone.0031000 e31000
51. Xueyi L., Lina C., Zhenbiao W., Qing H., Qiang L., Zhu P., Levels of circulating Th17 cells and regulatory T cells in ankylosing spondylitis patients with an inadequate response to anti-TNF-alpha therapy. Journal of Clinical Immunology 2013 33 1 151 161
52. Jandus C., Bioley G., Rivals J. P., Dudler J., Speiser D., Romero P., Increased numbers of circulating polyfunctional Th17 memory cells in patients with seronegative spondylarthritides. Arthritis and Rheumatism 2008 58 8 2307 2317 2-s2.0-49449115544 10.1002/art.23655
53. Mei Y., Pan F., Gao J., Ge R., Duan Z., Zeng Z., Liao F., Xia G., Wang S., Xu S., Xu J., Zhang L., Ye D., Increased serum IL-17 and IL-23 in the patient with ankylosing spondylitis. Clinical Rheumatology 2011 30 2 269 273 2-s2.0-79954450170 10.1007/s10067-010-1647-4
54. Kenna T. J., Davidson S. I., Duan R., Bradbury L. A., McFarlane J., Smith M., Weedon H., Street S., Thomas R., Thomas G. P., Brown M. A., Enrichment of circulating interleukin-17-secreting interleukin-23 receptor-positive γ / δ T cells in patients with active ankylosing spondylitis. Arthritis and Rheumatism 2012 64 5 1420 1429 2-s2.0-84858644639 10.1002/art.33507
55. Maksymowych W. P., Chiowchanwisawakit P., Clare T., Pedersen S. J., Østergaard M., Lambert R. G. W., Inflammatory lesions of the spine on magnetic resonance imaging predict the development of new syndesmophytes in ankylosing spondylitis evidence of a relationship between inflammation and new bone formation. Arthritis and Rheumatism 2009 60 1 93 102 2-s2.0-58249103888 10.1002/art.24132
56. Maksymowych W. P., Elewaut D., Schett G., Motion for debate: The development of ankylosis in ankylosing spondylitis is largely dependent on inflammation. Arthritis and Rheumatism 2012 64 6 1713 1719
57. Schett G., Independent development of inflammation and new bone formation in ankylosing spondylitis. Arthritis and Rheumatism 2012 10.1002/art.34441
58. van der Heijde D., Landewé R., Einstein S., Ory P., Vosse D., Ni L., Lin S. L., Tsuji W., Davis J. C. Jr., Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept. Arthritis and Rheumatism 2008 58 5 1324 1331 2-s2.0-43949140512 10.1002/art.23471 (Pubitemid 351705922)
59. Francisco L. M., Sage P. T., Sharpe A. H., The PD-1 pathway in tolerance and autoimmunity. Immunological Reviews 2010 236 1 219 242 2-s2.0-77953747963 10.1111/j.1600-065X.2010.00923.x
60. Campbell D. J., Koch M. A., Phenotypical and functional specialization of FOXP3+ regulatory T cells. Nature Reviews Immunology 2011 11 2 119 130 2-s2.0-79251500661 10.1038/nri2916
61. Azizi E., Massoud A., Amirzargar A. A., Mahmoudi M., Soleimanifar N., Rezaei N., Jamshidi A. R., Nikbin B., Nicknam M. H., Association of CTLA4 gene polymorphism in iranian patients with ankylosing spondylitis. Journal of Clinical Immunology 2010 30 2 268 271 2-s2.0-77953537163 10.1007/s10875-009- 9356-y
62. Lee Y. H., Ji J. D., Sohn J., Song G. G., Polymorphisms of CTLA-4 exon 1 +49, CTLA-4 promoter -318 and Fas promoter -670 in spondyloarthropathies. Clinical Rheumatology 2001 20 6 420 422 2-s2.0-0034747256 10.1007/s100670170007 (Pubitemid 33130478)
63. Lee W. Y., Chang Y. H., Lo M. K., Chang C. P., Yang S. C., Yang T. P., Ho K. T., Juan C. W., Shiau M. Y., Polymorphisms of cytotoxic T lymphocyte-associated antigen-4 and cytokine genes in Taiwanese patients with ankylosing spondylitis. Tissue Antigens 2010 75 2 119 126 2-s2.0-73949102296 10.1111/j.1399-0039.2009.01411.x
64. Liu X., Hu L. H., Li Y. R., Chen F. H., Ning Y., Yao Q. F., Programmed cell death 1 gene polymorphisms is associated with ankylosing spondylitis in Chinese Han population. Rheumatology International 2011 31 2 209 213 2-s2.0-79954442996 10.1007/s00296-009-1264-1
65. Soleimanifar N., Amirzargar A. A., Mahmoudi M., Pourfathollah A. A., Azizi E., Jamshidi A. R., Rezaei N., Tahoori M. T., Bidad K., Nikbin B., Nicknam M. H., Study of programmed cell death 1 (PDCD1) gene polymorphims in Iranian patients with ankylosing spondylitis. Inflammation 2011 34 6 707 712 2-s2.0-80053148154 10.1007/s10753-010-9282-4
66. Huang C. H., Wong R. H., Wei J. C. C., Tsay M. D., Chen W. C., Chen H. Y., Shih W. T., Chiou S. P., Tu Y. C., Lee H. S., Effects of genetic polymorphisms of programmed cell death 1 and its ligands on the development of ankylosing spondylitis. Rheumatology 2011 50 10 1809 1813 2-s2.0-80053156118 10.1093/rheumatology/ker211
67. Lee S. H., Lee Y. A., Woo D. H., Song R., Park E. K., Ryu M. H., Kim Y. H., Kim K. S., Hong S. J., Yoo M. C., Yang H. I., Association of the programmed cell death 1 (PDCD1) gene polymorphism with ankylosing spondylitis in the Korean population. Arthritis Research and Therapy 2006 8 6, article R163 2-s2.0-34247597636 10.1186/ar2071
68. Yang Q., Liu Y., Liu D., Zhang Y., Mu K., Association of polymorphisms in the programmed cell death 1 (PD-1) and PD-1 ligand genes with ankylosing spondylitis in a Chinese population. Clinical and Experimental Rheumatology 2011 29 1 13 18 2-s2.0-79955651491
69. Wu Y., Ren M., Yang R., Liang X., Ma Y., Tang Y., Huang L., Ye J., Chen K., Wang P., Shen H., Reduced immunomodulation potential of bone marrow-derived mesenchymal stem cells induced CCR4+CCR6+ Th/Treg cell subset imbalance in ankylosing spondylitis. Arthritis Research and Therapy 2011 13 1, article R29 2-s2.0-79951687194 10.1186/ar3257
70. Zhao S. S., Hu J. W., Wang J., Lou X. J., Zhou L. L., Inverse correlation between CD4+CD25highCD127low/- regulatory T-cells and serum immunoglobulin A in patients with new-onset ankylosing spondylitis. Journal of International Medical Research 2011 39 5 1968 1974 2-s2.0-80155175623
71. Appel H., Wu P., Scheer R., Kedor C., Sawitzki B., Thiel A., Radbruch A., Sieper J., Syrbe U., Synovial and peripheral blood CD4+FoxP3+ T cells in spondyloarthritis. Journal of Rheumatology 2011 38 11 2445 2451 2-s2.0-80155126034 10.3899/jrheum.110377
72. Tian Z., Gershwin M. E., Zhang C., Regulatory NK cells in autoimmune disease. Journal of Autoimmunity 2012 39 3 206 215
73. Azuz-Lieberman N., Markel G., Mizrahi S., Gazit R., Hanna J., Achdout H., Gruda R., Katz G., Arnon T. I., Battat S., Zamir E., Adawi M., Mader R., Mandelboim O., The involvement of NK cells in ankylosing spondylitis. International Immunology 2005 17 7 837 845 2-s2.0-26444529548 10.1093/intimm/dxh270 (Pubitemid 41417951)
74. French A. R., Yokoyama W. M., Natural killer cells and autoimmunity. Arthritis Research and Therapy 2004 6 1 8 14 2-s2.0-1342333777 (Pubitemid 38256082)
75. Park Y. W., Kee S. J., Cho Y. N., Lee E. H., Lee H. Y., Kim E. M., Shin M. H., Park J. J., Kim T. J., Lee S. S., Yoo D. H., Kang H. S., Impaired differentiation and cytotoxicity of natural killer cells in systemic lupus erythematosus. Arthritis and Rheumatism 2009 60 6 1753 1763 2-s2.0-66449101426 10.1002/art.24556
76. Aramaki T., Ida H., Izumi Y., Fujikawa K., Huang M., Arima K., Tamai M., Kamachi M., Nakamura H., Kawakami A., Origuchi T., Matsuoka N., Eguchi K., A significantly impaired natural killer cell activity due to a low activity on a per-cell basis in rheumatoid arthritis. Modern Rheumatology 2009 19 3 245 252 2-s2.0-67349201668 10.1007/s10165-009-0160-6
77. Cameron A. L., Kirby B., Griffiths C. E. M., Circulating natural killer cells in psoriasis. British Journal of Dermatology 2003 149 1 160 164 2-s2.0-0041633632 10.1046/j.1365-2133.2003.05319.x (Pubitemid 36966527)
78. Schepis D., Gunnarsson I., Eloranta M. L., Lampa J., Jacobson S. H., Kärre K., Berg L., Increased proportion of CD56bright natural killer cells in active and inactive systemic lupus erythematosus. Immunology 2009 126 1 140 146 10.1111/j.1365-2567.2008.02887.x
79. Szántó S., Aleksza M., Mihály E., Lakos G., Szabó Z., Végvári A., Sipka S., Szekanecz Z., Intracytoplasmic cytokine expression and T cell subset distribution in the peripheral blood of patients with ankylosing spondylitis. Journal of Rheumatology 2008 35 12 2372 2375 2-s2.0-57349120591 10.3899/jrheum.070839
80. Mousavi T., Poormoghim H., Moradi M., Tajik N., Shahsavar F., Soofi M., Phenotypic study of natural killer cell subsets in ankylosing spondylitis patients. Iranian Journal of Allergy, Asthma and Immunology 2009 8 4 193 198 2-s2.0-77951581599
81. Ciccia F., Accardo-Palumbo A., Alessandro R., Interleukin-22 and interleukin-22-producing NKp44+ natural killer cells in subclinical gut inflammation in ankylosing spondylitis. Arthritis and Rheumatism 2012 64 6 1869 1878 10.1002/art.34355
82. Zvyagin I. V., Mamedov I. Z., Britanova O. V., Staroverov D. B., Nasonov E. L., Bochkova A. G., Chkalina A. V., Kotlobay A. A., Korostin D. O., Rebrikov D. V., Lukyanov S., Lebedev Y. B., Chudakov D. M., Contribution of functional KIR3DL1 to ankylosing spondylitis. Cellular and Molecular Immunology 2010 7 6 471 476 2-s2.0-78049488576 10.1038/cmi.2010.42
83. Wong-Baeza I., Ridley A., Shaw J., Hatano H., Rysnik O., McHugh K., Piper C., Brackenbridge S., Fernandes R., Chan A., Bowness P., Kollnberger S., KIR3DL2 binds to HLA-B27 dimers and free H chains more strongly than other HLA class I and promotes the expansion of T cells in ankylosing spondylitis. Journal of Immunology 2013 190 7 3216 3224 10.4049/jimmunol.1202926
84. Wang S., Li G., Ge R., Duan Z., Zeng Z., Zhang T., Gao J., Yang T., Liu S., Wu S., Fan D., Xu S., Xu J., Zhang L., Shuai Z., Ye D., Zou Y., Pan F., Association of KIR genotype with susceptibility to HLA-B27-positive ankylosing spondylitis. Modern Rheumatology 2013 23 3 538 541 10.1007/s10165-012-0692-z
85. Jiao Y. L., Zhang B. C., You L., Li J. F., Zhang J., Ma C. Y., Cui B., Wang L. C., Chen Z. J., Zhao Y. R., Polymorphisms of KIR gene and HLA-C alleles: possible association with susceptibility to HLA-B27-positive patients with ankylosing spondylitis. Journal of Clinical Immunology 2010 30 6 840 844 2-s2.0-78651289009 10.1007/s10875-010-9444-z
86. Díaz-Peña R., Vidal-Castiñeira J. R., Alonso-Arias R., Suarez-Alvarez B., Vicario J. L., Solana R., Collantes E., López- Vázquez A., Martínez-Borra J., López-Larrea C., Association of the KIR3DS1-013 and KIR3DL1-004 alleles with susceptibility to ankylosing Spondylitis. Arthritis and Rheumatism 2010 62 4 1000 1006 2-s2.0-77950534841 10.1002/art.27332
87. Díaz-Peña R., Blanco-Gelaz M. A., Suárez- Álvarez B., Martínez-Borra J., López-Vázquez A., Alonso-Arias R., Brüges-Armas J., Vidal-Castiñeira J. R., López-Larrea C., Activating KIR genes are associated with ankylosing spondylitis in Asian populations. Human Immunology 2008 69 7 437 442 10.1016/j.humimm.2008.04.012
88. Tajik N., Shahsavar F., Poormoghim H., Radjabzadeh M. F., Mousavi T., Jalali A., KIR3DL1+HLA-B Bw4 Ile80 and KIR2DS1+HLA-C2 combinations are both associated with ankylosing spondylitis in the Iranian population. International Journal of Immunogenetics 2011 38 5 403 409 2-s2.0-80052849261 10.1111/j.1744-313X.2011.01024.x
89. Mousavi T., Poormoghim H., Moradi M., Tajik N., Shahsavar F., Asadifar B., Inhibitory killer cell immunoglobulin-like receptor KIR3DL1 in combination with HLA-B Bw4iso protect against Ankylosing spondylitis. Iranian Journal of Immunology 2010 7 2 88 95 2-s2.0-79952288662
90. Harvey D., Pointon J. J., Sleator C., Meenagh A., Farrar C., Sun J. Y., Senitzer D., Middleton D., Brown M. A., Wordsworth B. P., Analysis of killer immunoglobulin-like receptor genes in ankylosing spondylitis. Annals of the Rheumatic Diseases 2009 68 4 595 598 2-s2.0-65249162792 10.1136/ard.2008.095927
91. Pratt A. G., Isaacs J. D., Mattey D. L., Current concepts in the pathogenesis of early rheumatoid arthritis. Best Practice and Research: Clinical Rheumatology 2009 23 1 37 48 2-s2.0-60449096601 10.1016/j.berh.2008.08.002
92. Conigliaro P., Scrivo R., Valesini G., Perricone R., Emerging role for NK cells in the pathogenesis of inflammatory arthropathies. Autoimmunity Reviews 2011 10 10 577 581 2-s2.0-80051671636 10.1016/j.autrev.2011.04.017
93. Rivino L., Gruarin P., Häringer B., Steinfelder S., Lozza L., Steckel B., Weick A., Sugliano E., Jarrossay D., Kühl A. A., Loddenkemper C., Abrignani S., Sallusto F., Lanzavecchia A., Geginat J., CCR6 is expressed on an IL-10-producing, autoreactive memory T cell population with context-dependent regulatory function. Journal of Experimental Medicine 2010 207 3 565 577 2-s2.0-77949511548 10.1084/jem.20091021
94. Comerford I., Bunting M., Fenix K., Haylock-Jacobs S., Litchfield W., Harata-Lee Y., Turvey M., Brazzatti J., Gregor C., Nguyen P., Kara E., McColl S. R., An immune paradox: how can the same chemokine axis regulate both immune tolerance and activation?: CCR6/CCL20: a chemokine axis balancing immunological tolerance and inflammation in autoimmune disease. BioEssays 2010 32 12 1067 1076 2-s2.0-78649512344 10.1002/bies.201000063
95. Varona R., Cadenas V., Gómez L., Martínez-A C., Márquez G., CCR6 regulates CD4+ T-cell-mediated acute graft-versus-host disease responses. Blood 2005 106 1 18 26 (Pubitemid 40967169)
96. Kochi Y., Okada Y., Suzuki A., Ikari K., Terao C., Takahashi A., Yamazaki K., Hosono N., Myouzen K., Tsunoda T., Kamatani N., Furuichi T., Ikegawa S., Ohmura K., Mimori T., Matsuda F., Iwamoto T., Momohara S., Yamanaka H., Yamada R., Kubo M., Nakamura Y., Yamamoto K., A regulatory variant in CCR6 is associated with rheumatoid arthritis susceptibility. Nature Genetics 2010 42 6 515 519 2-s2.0-77952885768 10.1038/ng.583
97. Ruth J. H., Shahrara S., Park C. C., Morel J. C. M., Kumar P., Qin S., Koch A. E., Role of macrophage inflammatory protein-3 α and its ligand CCR6 in rheumatoid arthritis. Laboratory Investigation 2003 83 4 579 588 2-s2.0-0037392702 (Pubitemid 36457712)
98. Cohen C. J., Karaderi T., Pointon J. J., Wordsworth B. P., A CCR6 variant strongly associated with rheumatoid arthritis in two populations is not associated with ankylosing spondylitis. Rheumatology International 2012 2-s2.0-84859635246 10.1007/s00296-012-2404-6
99. Chang W. C., Woon P. Y., Wei J. C., Chang C. M., Hsu Y. W., Guo Y. C., Hwang D. Y., Kochi Y., Yen J. H., A single-nucleotide polymorphism of CCR6 (rs3093024) is associated with susceptibility to rheumatoid arthritis but not ankylosing spondylitis, in a Taiwanese population. Journal of Rheumatology 2012 39 8 1765 1766 10.3899/jrheum.120040
100. Acosta-Rodriguez E. V., Rivino L., Geginat J., Jarrossay D., Gattorno M., Lanzavecchia A., Sallusto F., Napolitani G., Surface phenotype and antigenic specificity of human interleukin 17-producing T helper memory cells. Nature Immunology 2007 8 6 639 646 2-s2.0-34249079176 10.1038/ni1467 (Pubitemid 46785128)
101. Annunziato F., Cosmi L., Santarlasci V., Maggi L., Liotta F., Mazzinghi B., Parente E., Filì L., Ferri S., Frosali F., Giudici F., Romagnani P., Parronchi P., Tonelli F., Maggi E., Romagnani S., Phenotypic and functional features of human Th17 cells. Journal of Experimental Medicine 2007 204 8 1849 1861 2-s2.0-34547734621 10.1084/jem.20070663 (Pubitemid 47240944)
102. Moretta A., Bottino C., Commentary: regulated equilibrium between opposite signals: a general paradigm for T cell function? European Journal of Immunology 2004 34 8 2084 2088 2-s2.0-4344656536 10.1002/eji.200425388 (Pubitemid 39256089)
103. Fernández-Mestre M., Sánchez K., Balbás O., Gendzekhzadze K., Ogando V., Cabrera M., Layrisse Z., Influence of CTLA-4 gene polymorphism in autoimmune and infectious diseases. Human Immunology 2009 70 7 532 535 2-s2.0-67449126847 10.1016/j.humimm.2009.03.016
104. Gonzalez-Escribano M. F., Rodriguez R., Valenzuela A., Garcia A., Garcia-Lozano J. R., Nunez-Roldan A., CTLA4 polymorphisms in Spanish patients with rheumatoid arthritis. Tissue Antigens 1999 53 3 296 300 2-s2.0-0033065858 10.1034/j.1399-0039.1999.530311.x (Pubitemid 29121834)
105. Rodríguez M. R., Núñez-Roldán A., Aguilar F., Valenzuela A., García A., González-Escribano M. F., Association of the CTLA4 3′ untranslated region polymorphism with the susceptibility to rheumatoid arthritis. Human Immunology 2002 63 1 76 81 2-s2.0-0036146832 10.1016/S0198-8859(01)00358-5 (Pubitemid 34074639)
106. Mäurer M., Loserth S., Kolb-Mäurer A., Ponath A., Wiese S., Kruse N., Rieckmann P., A polymorphism in the human cytotoxic T-lymphocyte antigen 4 (CTLA4) gene (exon 1 +49) alters T-cell activation. Immunogenetics 2002 54 1 1 8 2-s2.0-0036256007 10.1007/s00251-002-0429-9 (Pubitemid 34492947)
107. Toussirot É., Saas P., Deschamps M., Pouthier F., Perrot L., Perruche S., Chabod J., Tiberghien P., Wendling D., Increased production of soluble CTLA-4 in patients with spondylarthropathies correlates with disease activity. Arthritis Research and Therapy 2009 11 4, article R101 2-s2.0-68949149643 10.1186/ar2747
108. Zhang G., Liu Z., Duan S., Han Q., Li Z., Lv Y., Chen J., Lou S., Li N., Association of polymorphisms of programmed cell death-1 gene with chronic hepatitis B virus infection. Human Immunology 2010 71 12 1209 1213 2-s2.0-78149413692 10.1016/j.humimm.2010.08.014
109. Burton P. R., Clayton D. G., Cardon L. R., Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants. Nature Genetics 2007 39 11 1329 1337 (Pubitemid 350041542)
110. Reveille J. D., Sims A. M., Danoy P., Evans D. M., Leo P., Pointon J. J., Jin R., Zhou X., Bradbury L. A., Appleton L. H., Davis J. C., Diekman L., Doan T., Dowling A., Duan R., Duncan E. L., Farrar C., Hadler J., Harvey D., Karaderi T., Mogg R., Pomeroy E., Pryce K., Taylor J., Savage L., Deloukas P., Kumanduri V., Peltonen L., Ring S. M., Whittaker P., Glazov E., Thomas G. P., Maksymowych W. P., Inman R. D., Ward M. M., Stone M. A., Weisman M. H., Wordsworth B. P., Brown M. A., Genome-wide association study of ankylosing spondylitis identifies non-MHC susceptibility loci. Nature Genetics 2010 42 2 123 127 2-s2.0-75749085686 10.1038/ng.513
111. Evans D. M., Spencer C. C., Pointon J. J., Interaction between ERAP1 and HLA-B27 in ankylosing spondylitis implicates peptide handling in the mechanism for HLA-B27 in disease susceptibility. Nature Genetics 2011 43 8 761 767 10.1038/ng.873
112. Tsui F. W. L., Haroon N., Reveille J. D., Rahman P., Chiu B., Tsui H. W., Inman R. D., Association of an ERAP1 ERAP2 haplotype with familial ankylosing spondylitis. Annals of the Rheumatic Diseases 2010 69 4 733 736 2-s2.0-77950331522 10.1136/ard.2008.103804
113. Pimentel-Santos F. M., Ligeiro D., Matos M., Mourão A. F., Sousa E., Pinto P., Ribeiro A., Sousa M., Barcelos A., Godinho F., Cruz M., Fonseca J. E., Guedes-Pinto H., Trindade H., Evans D. M., Brown M. A., Branco J. C., Alves de Matos A., Ribeiro C., Pimentão J. B., Mateus M., Nero P., Araújo P., Barros R., Falcão S., Pinto T. L., Castelão W., Caetano-Lopes J., Silva C., Simões E., Madeira H., Santos H., Patto J. V., Ferreira J., Micaelo M., Mediavilla M. J., Branco P. S., Canas Da Silva J., Garcês S., Tavares V., Araújo D., Costa J. A., Costa L., Afonso M. C., Bogas M., Alcino S., Cunha I., Redondo J., Cravo A. R., Sequeira G., Santos R. A., Carvalho M. E., Association of IL23R and ERAP1 genes with ankylosing spondylitis in a Portuguese population. Clinical and Experimental Rheumatology 2009 27 5 800 806 2-s2.0-72949094188
114. Harvey D., Pointon J. J., Evans D. M., Karaderi T., Farrar C., Appleton L. H., Sturrock R. D., Stone M. A., Oppermann U., Brown M. A., Wordsworth B. P., Investigating the genetic association between ERAP1 and ankylosing spondylitis. Human Molecular Genetics 2009 18 21 4204 4212 2-s2.0-70349991884 10.1093/hmg/ddp371
115. Maksymowych W. P., Inman R. D., Gladman D. D., Reeve J. P., Pope A., Rahman P., Association of a specific ERAP1/ARTS1 haplotype with disease susceptibility in ankylosing spondylitis. Arthritis and Rheumatism 2009 60 5 1317 1323 2-s2.0-66049103503 10.1002/art.24467
116. Davidson S. I., Wu X., Liu Y., Wei M., Danoy P. A., Thomas G., Cai Q., Sun L., Duncan E., Wang N., Yu Q., Xu A., Fu Y., Brown M. A., Xu H., Association of ERAP1, but not IL23R, with ankylosing spondylitis in a Han Chinese population. Arthritis and Rheumatism 2009 60 11 3263 3268 2-s2.0-70350525335
117. Pazár B., Sáfrány E., Gergely P., Szántó S., Szekanecz Z., Poór G., Association of ARTS1 gene polymorphisms with ankylosing spondylitis in the Hungarian population: The rs27044 variant is associated with HLA-B-2705 subtype in Hungarian patients with ankylosing spondylitis. Journal of Rheumatology 2010 37 2 379 384 2-s2.0-76649083225 10.3899/jrheum.090806
118. Choi C. B., Kim T. H., Jun J. B., Lee H. S., Shim S. C., Lee B., Pope A., Uddin M., Rahman P., Inman R. D., ARTS1 polymorphisms are associated with ankylosing spondylitis in Koreans. Annals of the Rheumatic Diseases 2010 69 3 582 584 2-s2.0-77949458118 10.1136/ard.2008.105296
119. Davidson S. I., Liu Y., Danoy P. A., Wu X., Thomas G. P., Jiang L., Sun L., Wang N., Han J., Han H., Reveille J. D., Evans D. M., Savage L., Ward M. M., Weisman M. H., Wordsworth B. P., Visscher P. M., Brown M. A., Xu H., Association of STAT3 and TNFRSF1A with ankylosing spondylitis in Han Chinese. Annals of the Rheumatic Diseases 2011 70 2 289 292 2-s2.0-78751706438 10.1136/ard.2010.133322
120. Wu W., Ding Y., Chen Y., Hua Z., Liu H., Wang H., Jiao G., Susceptibility to ankylosing spondylitis: evidence for the role of ERAP1, TGFb1 and TLR9 gene polymorphisms. Rheumatology International 2012 32 8 2517 2521 2-s2.0-79960467748 10.1007/s00296-011-1994-8
121. Szczypiorska M., Sánchez A., Bartolomé N., Arteta D., Sanz J., Brito E., Fernández P., Collantes E., Martínez A., Tejedor D., Artieda M., Mulero J., ERAP1 polymorphisms and haplotypes are associated with ankylosing spondylitis susceptibility and functional severity in a Spanish population. Rheumatology 2011 50 11 1969 1975 2-s2.0-84855168152
122. Li C., Lin Z., Xie Y., Guo Z., Huang J., Wei Q., Li Q. X., Wang X., Cao S., Liao Z., Xu M., Shen Y., Gu J., ERAP1 is associated with ankylosing spondylitis in Han Chinese. Journal of Rheumatology 2011 38 2 317 321 2-s2.0-79551706070 10.3899/jrheum.100013
123. Mahmoudi M., Jamshidi A. R., Amirzargar A. A., Farhadi E., Nourijelyani K., Fallahi S., Oraei M., Noori S., Nicknam M. H., Association between endoplasmic reticulum aminopeptidase-1 (ERAP-1) and susceptibility to ankylosing spondylitis in Iran. Iranian Journal of Allergy, Asthma, and Immunology 2012 11 4 294 300
124. Lee Y. H., Choi S. J., Ji J. D., Song G. G., Associations between ERAP1 polymorphisms and ankylosing spondylitis susceptibility: a meta-analysis. Inflammation Research 2011 60 11 999 1003 2-s2.0-80855130749 10.1007/s00011-011-0374-x
125. Chen R., Yao L., Meng T., Xu W., The association between seven ERAP1 polymorphisms and ankylosing spondylitis susceptibility: a meta-analysis involving 8,530 cases and 12,449 controls. Rheumatology International 2011 32 4 909 914 2-s2.0-78651075526 10.1007/s00296-010-1712-y
126. Chatzikyriakidou A., Georgiou I., Voulgari P. V., Drosos A. A., The role of tumor necrosis factor (TNF)- α and TNF receptor polymorphisms in susceptibility to ankylosing spondylitis. Clinical and Experimental Rheumatology 2009 27 4 645 648 2-s2.0-70350149400
127. Lee Y. H., Song G. G., Lack of association of TNF-alpha promoter polymorphisms with ankylosing spondylitis: a meta-analysis. Rheumatology 2009 48 11 1359 1362 2-s2.0-73349132069
128. Li B., Wang P., Li H., The association between TNF- α promoter polymorphisms and ankylosing spondylitis: a meta-analysis. Clinical Rheumatology 2010 29 9 983 990 2-s2.0-77956184319 10.1007/s10067-010-1499-y
129. Poddubnyy D. A., Märker-Hermann E., Kaluza-Schilling W., Zeidler H., Braun J., Listing J., Sieper J., Rudwaleit M., Relation of HLA-B27, tumor necrosis factor- α promoter gene polymorphisms, and T cell cytokine production in ankylosing spondylitis-a comprehensive genotype-phenotype analysis from an observational cohort. Journal of Rheumatology 2011 38 11 2436 2441 2-s2.0-80155146569 10.3899/jrheum.110130
130. Romero-Sánchez C., Londoño J., Delgado G., Jaimes D. A., de Avila J., Mora A., Ávila M., Castellanos J., Briceño I., Valle-Oñate R., Association of tumor necrosis factor alpha-308 promoter polymorphism with spondyloarthritides patients in Colombia. Rheumatology International 2012 32 7 2195 2197 2-s2.0-79960472947 10.1007/s00296-011-1883-1
131. Vargas-Alarcón G., Casasola-Vargas J., Rodríguez- Pérez J. M., Huerta-Sil G., Pérez-Hernández N., Londoño J., Pacheco-Tena C., Cardiel M. H., Granados J., Burgos-Vargas R., Tumor necrosis factor- α promoter polymorphisms in mexican patients with spondyloarthritis. Human Immunology 2006 67 10 826 832 2-s2.0-33750006798 10.1016/j.humimm.2006.07.009 (Pubitemid 44572596)
132. Nicknam M. H., Mahmoudi M., Amirzargar A. A., Jamshidi A. R., Rezaei N., Nikbin B., HLA-B27 subtypes and tumor necrosis factor α promoter region polymorphism in Iranian patients with ankylosing spondylitis. European Cytokine Network 2009 20 1 17 20 2-s2.0-66249084824 10.1684/ecn.2009.0143
133. Shiau M. Y., Lo M. K., Chang C. P., Yang T. P., Ho K. T., Chang Y. H., Association of tumour necrosis factor α promoter polymorphisms with ankylosing spondylitis in Taiwan. Annals of the Rheumatic Diseases 2007 66 4 562 563 2-s2.0-34147218587 10.1136/ard.2006.065888 (Pubitemid 46580488)
134. Zúñiga J., Torres-García D., Jimenez L., Ramírez-Martínez G., Juárez-Nicolás F., Mujica F., Romero L. T., Acuña V., Cruz-Lagunas A., Ruíz-Saavedra D., Ramos C., Montaño M., Mendoza-Milla C., Vargas-Alarcón G., Pardo A., Selman M., PDCD1 gene polymorphisms in different Mexican ethnic groups and their role in the susceptibility to hypersensitivity pneumonitis. Clinical Biochemistry 2010 43 10-11 929 931 2-s2.0-77953693307 10.1016/j.clinbiochem. 2010.04.068
135. Kochan G., Krojer T., Harvey D., Fischer R., Chen L., Vollmar M., Von Delft F., Kavanagh K. L., Brown M. A., Bowness P., Wordsworth P., Kessler B. M., Oppermann U., Crystal structures of the endoplasmic reticulum aminopeptidase-1 (ERAP1) reveal the molecular basis for N-terminal peptide trimming. Proceedings of the National Academy of Sciences of the United States of America 2011 108 19 7745 7750 2-s2.0-79956348710 10.1073/pnas.1101262108
136. Kim S., Lee S., Shin J., Kim Y., Evnouchidou I., Kim D., Kim Y. K., Kim Y. E., Ahn J. H., Riddell S. R., Stratikos E., Kim V. N., Ahn K., Human cytomegalovirus microRNA miR-US4-1 inhibits CD8+ T cell responses by targeting the aminopeptidase ERAP1. Nature Immunology 2011 12 10 984 991 2-s2.0-80052966924 10.1038/ni.2097
137. Goto Y., Tanji H., Hattori A., Tsujimoto M., Glutamine-181 is crucial in the enzymatic activity and substrate specificity of human endoplasmic-reticulum aminopeptidase-1. Biochemical Journal 2008 416 1 109 115 2-s2.0-56049109055 10.1042/BJ20080965
138. Saveanu L., Carroll O., Lindo V., Del Val M., Lopez D., Lepelletier Y., Greer F., Schomburg L., Fruci D., Niedermann G., van Endert P. M., Concerted peptide trimming by human ERAP1 and ERAP2 aminopeptidase complexes in the endoplasmic reticulum. Nature Immunology 2005 6 7 689 697 2-s2.0-22144442460 10.1038/ni1208 (Pubitemid 41716742)
139. Kisselev A. F., Akopian T. N., Woo K. M., Goldberg A. L., The sizes of peptides generated from protein by mammalian 26 and 20 S proteasomes. Implications for understanding the degradative mechanism and antigen presentation. Journal of Biological Chemistry 1999 274 6 3363 3371 2-s2.0-0033525086 10.1074/jbc.274.6.3363 (Pubitemid 29077173)
140. Androlewicz M. J., Anderson K. S., Cresswell P., Evidence that transporters associated with antigen processing translocate a major histocompatibility complex class I-binding peptide into the endoplasmic reticulum in an ATP-dependent manner. Proceedings of the National Academy of Sciences of the United States of America 1993 90 19 9130 9134 2-s2.0-0027424659 10.1073/pnas.90.19.9130 (Pubitemid 23306465)
141. Neefjes J. J., Momburg F., Hammerling G. J., Selective and ATP-dependent translocation of peptides by the MHC-encoded transporter. Science 1993 261 5122 769 771 2-s2.0-0027239749 (Pubitemid 23278394)
142. van Endert P. M., Tampé R., Meyer T. H., Tisch R., Bach J. F., McDevitt H. O., A sequential model for peptide binding and transport by the transporters associated with antigen processing. Immunity 1994 1 6 491 500 2-s2.0-0028501327
143. York I. A., Chang S. C., Saric T., Keys J. A., Favreau J. M., Goldberg A. L., Rock K. L., The ER aminopeptidase ERAP I enhances or limits antigen presentation by trimming epitopes to 8-9 residues. Nature Immunology 2002 3 12 1177 1184 2-s2.0-0036884090 10.1038/ni860 (Pubitemid 35469702)
144. Chang S. C., Momburg F., Bhutani N., Goldberg A. L., The ER aminopeptidase, ERAP1, trims precursors to lengths of MHC class I peptides by a "molecular ruler" mechanism. Proceedings of the National Academy of Sciences of the United States of America 2005 102 47 17107 17112 2-s2.0-28044456942 10.1073/pnas.0500721102 (Pubitemid 41692691)
145. Cui X., Hawari F., Alsaaty S., Lawrence M., Combs C. A., Geng W., Rouhani F. N., Miskinis D., Levine S. J., Identification of ARTS-1 as a novel TNFR1-binding protein that promotes TNFR1 ectodomain shedding. Journal of Clinical Investigation 2002 110 4 515 526 2-s2.0-0036679366 10.1172/JCI200213847 (Pubitemid 34919706)
146. Cui X., Rouhani F. N., Hawari F., Levine S. J., Shedding of the type II IL-1 decoy receptor requires a multifunctional aminopeptidase, aminopeptidase regulator of TNF receptor type 1 shedding. Journal of Immunology 2003 171 12 6814 6819 2-s2.0-0345735829 (Pubitemid 37532116)
147. Cui X., Rouhani F. N., Hawari F., Levine S. J., An aminopeptidase, ARTS-1, is required for interleukin-6 receptor shedding. Journal of Biological Chemistry 2003 278 31 28677 28685 2-s2.0-0042206848 10.1074/jbc.M300456200 (Pubitemid 36935774)
148. Haroon N., Tsui F. W. L., Chiu B., Tsui H. W. O., Inman R. D., Serum cytokine receptors in ankylosing spondylitis: relationship to inflammatory markers and endoplasmic reticulum aminopeptidase polymorphisms. Journal of Rheumatology 2010 37 9 1907 1910 2-s2.0-77956470985 10.3899/jrheum.100019
149. Goto Y., Ogawa K., Hattori A., Tsujimoto M., Secretion of endoplasmic reticulum aminopeptidase 1 is involved in the activation of macrophages induced by lipopolysaccharide and interferon- γ Journal of Biological Chemistry 2011 286 24 21906 21914 2-s2.0-79958709420 10.1074/jbc.M111.239111
150. Brown M. A., Progress in the genetics of ankylosing spondylitis. Briefings in Functional Genomics 2011 10 5 249 257 2-s2.0-80054966401 10.1093/bfgp/elr023
151. Fridman W. H., Bonnerot C., Daeron M., Amigorena S., Teillaud J. L., Sautes C., Structural bases of Fc γ receptor functions. Immunological Reviews 1992 125 49 76 2-s2.0-0026611219
152. Yada A., Ebihara S., Matsumura K., Endo S., Maeda T., Nakamura A., Akiyama K., Aiba S., Takai T., Accelerated antigen presentation and elicitation of humoral response in vivo by Fc γ RIIB- and Fc γ RI/III-mediated immune complex uptake. Cellular Immunology 2003 225 1 21 32 2-s2.0-0345414168 10.1016/j.cellimm.2003.09.008 (Pubitemid 37468459)
153. Gessner J. E., Heiken H., Tamm A., Schmidt R. E., The IgG Fc receptor family. Annals of Hematology 1998 76 6 231 248 2-s2.0-0031873992 10.1007/s002770050396 (Pubitemid 28321079)
154. Nimmerjahn F., Ravetch J. V., Fc γ receptors as regulators of immune responses. Nature Reviews Immunology 2008 8 1 34 47 2-s2.0-37549036732 10.1038/nri2206
155. Takai T., Fc receptors and their role in immune regulation and autoimmunity. Journal of Clinical Immunology 2005 25 1 1 18 2-s2.0-15244358941 10.1007/s10875-005-0353-8 (Pubitemid 40386174)
156. Stefanescu R. N., Olferiev M., Liu Y. I., Pricop L., Inhibitory Fc gamma receptors: from gene to disease. Journal of Clinical Immunology 2004 24 4 315 326 2-s2.0-3442878238 10.1023/B:JOCI.0000029105.47772.04 (Pubitemid 39005564)
157. Phillips N. E., Parker D. C., Fc-dependent inhibition of mouse B cell activation by whole anti- antibodies. Journal of Immunology 1983 130 2 602 606 2-s2.0-0020660265 (Pubitemid 13186273)
158. Pritchard N. R., Cutler A. J., Uribe S., Chadban S. J., Morley B. J., Smith K. G. C., Autoimmune-prone mice share a promoter haplotype associated with reduced expression and function of the Fc receptor Fc γ RII. Current Biology 2000 10 4 227 230 2-s2.0-0034708252 10.1016/S0960-9822(00)00344-4 (Pubitemid 30146790)
159. Su K., Li X., Edberg J. C., Wu J., Ferguson P., Kimberly R. P., A promoter haplotype of the immunoreceptor tyrosine-based inhibitory motif-bearing Fc γ RIIb alters receptor expression and associates with autoimmunity. II. Differential binding of GATA4 and Yin-Yang1 transcription factors and correlated receptor expression and function. Journal of Immunology 2004 172 11 7192 7199 2-s2.0-2442679050 (Pubitemid 38669164)
160. Blank M. C., Stefanescu R. N., Masuda E., Marti F., King P. D., Redecha P. B., Wurzburger R. J., Peterson M. G. E., Tanaka S., Pricop L., Decreased transcription of the human FCGR2B gene mediated by the -343 G/C promoter polymorphism and association with systemic lupus erythematosus. Human Genetics 2005 117 2-3 220 227 2-s2.0-26944456633 10.1007/s00439-005-1302-3 (Pubitemid 43136798)
161. Duan Z. H., Pan F. M., Zeng Z., Zhang T. C., Wang S., Li G. X., Mei Y., Gao J., Ge R., Ye D. Q., Zou Y. F., Xu S. Q., Xu J. H., Zhang L., The FCGR2B rs10917661 polymorphism may confer susceptibility to ankylosing spondylitis in Han Chinese: a casecontrol study. Scandinavian Journal of Rheumatology 2012 41 3 219 222 2-s2.0-84860549917 10.3109/03009742.2011.625972
162. de Jesús Durán-Avelar Ma., Vibanco-Pérez N., Rodríguez-Ocampo A. N., Agraz-Cibrian J. M., Peña-Virgen S., Zambrano-Zaragoza J. F., Bruges-Armas J., Humoral immune response to Salmonella sntigens and polymorphisms in receptors for the Fc of IgG in patients with ankylosing spondylitis. Clinical and Molecular Advances in Ankylosing Spondylitis 2012 Intech. http://www.intechopen.com/books/clinical-and-molecular- advances-in-ankylosing-spondylitis/humoral-immune-response-to-salmonella- antigens-and-polymorphisms-in-receptors-for-the-fc-of-igg-in-p 10.5772/28549
163. Zambrano-Zaragoza J. F., de Jesus D. A. M., Rodríguez-Ocampo A. N., García-Latorre E., Burgos-Vargas R., Dominguez-Lopez M. L., Pena-Virgen S., Vibanco-Pérez N., The 30-kDa band from Salmonella typhimurium: IgM, IgA and IgG antibody response in patients with ankylosing spondylitis. Rheumatology 2009 48 7 748 754 2-s2.0-67650067182 10.1093/rheumatology/kep113
164. Hjelholt A., Carlsen T., Deleuran B., Jurik A. G., Schiøttz- Christensen B., Christiansen G., Birkelund S., Increased levels of IgG antibodies against human HSP60 in patients with spondyloarthritis. PloS One 2013 8 2 e56210 10.1371/journal.pone.0056210
165. Morales-Lara M. J., Conesa-Zamora P., Garca-Simón M. S., Pedrero F., Santaclara V., Perez-Guillermo M., Soriano-Navarro E., Association between the FCGR3A V158F polymorphism and the clinical response to infliximab in rheumatoid arthritis and spondyloarthritis patients. Scandinavian Journal of Rheumatology 2010 39 6 518 520 2-s2.0-78649708666 10.3109/03009741003781969
166. van Hauwermeiren F., Vandenbroucke R. E., Libert C., Treatment of TNF mediated diseases by selective inhibition of soluble TNF or TNFR1. Cytokine and Growth Factor Reviews 2011 22 5-6 311 319 2-s2.0-82955236074 10.1016/j.cytogfr.2011.09.004
167. Tak P. P., Kalden J. R., Advances in rheumatology: new targeted therapeutics. Arthritis Research and Therapy 2011 13 1, article S5 2-s2.0-79958108824 10.1186/1478-6354-13-S1-S5
168. Chou C. T., Huo A. P., Chang H. N., Tsai C. Y., Chen W. S., Wang H. P., Cytokine production from peripheral blood mononuclear cells in patients with ankylosing spondylitis and their first-degree relatives. Archives of Medical Research 2007 38 2 190 195 2-s2.0-33846120589 10.1016/j.arcmed.2006.09.008 (Pubitemid 46080541)
169. Wendling D., Prati C., Biologic agents for treating ankylosing spondylitis: beyond TNF α antagonists. Joint Bone Spine 2011 78 6 542 544 2-s2.0-84855974706 10.1016/j.jbspin.2011.05.023
170. Braun J., Deodhar A., Dijkmans B., Geusens P., Sieper J., Williamson P., Xu W., Visvanathan S., Baker D., Goldstein N., van der Heijde D., Efficacy and safety of infliximab in patients with ankylosing spondylitis over a two-year period. Arthritis and Rheumatism 2008 59 9 1270 1278 2-s2.0-52249095365 10.1002/art.24001
171. van der Heijde D., Schiff M. H., Sieper J., Kivitz A. J., Wong R. L., Kupper H., Dijkmans B. A. C., Mease P. J., Davis J. C. Jr., Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial. Annals of the Rheumatic Diseases 2009 68 6 922 929 2-s2.0-67449116868 10.1136/ard.2007.087270
172. Saougou I., Markatseli T. E., Voulgari P. V., Drosos A. A., Maintained clinical response of infliximab treatment in ankylosing spondylitis: a 6-year long-term study. Joint Bone Spine 2010 77 4 325 329 2-s2.0-77954623685 10.1016/j.jbspin.2010.02.014
173. Arends S., Spoorenberg A., Houtman P. M., Leijsma M. K., Bos R., Kallenberg C. G., Groen H., Brouwer E., van der Veer E., The effect of three years of TNF alpha blocking therapy on markers of bone turnover and their predictive value for treatment discontinuation in patients with ankylosing spondylitis: a prospective longitudinal observational cohort study. Arthritis Research & Therapy 2012 14 2, article R98 10.1186/ar3823
174. Kang K. Y., Lee K. Y., Kwok S. K., Ju J. H., Park K. S., Hong Y. S., Kim H. Y., Park S. H., The change of bone mineral density according to treatment agents in patients with ankylosing spondylitis. Joint Bone Spine 2011 78 2 188 193 2-s2.0-79952242241 10.1016/j.jbspin.2010.05.010
175. Gallo E., Cabaleiro T., Román M., Abad-Santos F., Daudén E., Study of genetic polymorphisms in the tumor necrosis factor α promoter region in Spanish patients with psoriasis. Actas Dermo-Sifiliograficas 2012 103 4 301 307 2-s2.0-84859949600 10.1016/j.ad.2011.10.002
176. Kothari N., Bogra J., Abbas H., Kohli M., Malik A., Kothari D., Srivastava S., Singh P. K., Tumor Necrosis Factor gene polymorphism results in high TNF level in sepsis and septic shock. Cytokine 2013 61 2 676 681 10.1016/j.cyto.2012.11.016
177. Wilson A. G., Symons J. A., Mcdowell T. L., Mcdevitt H. O., Duff G. W., Effects of a polymorphism in the human tumor necrosis factor α promoter on transcriptional activation. Proceedings of the National Academy of Sciences of the United States of America 1997 94 7 3195 3199 2-s2.0-0030954180 10.1073/pnas.94.7.3195 (Pubitemid 27157287)
178. Seitz M., Wirthmüller U., Möller B., Villiger P. M., The -308 tumour necrosis factor- α gene polymorphism predicts therapeutic response to TNF α -blockers in rheumatoid arthritis and spondyloarthritis patients. Rheumatology 2007 46 1 93 96 2-s2.0-33845595254 10.1093/rheumatology/kel175 (Pubitemid 44932793)
179. Zalevsky J., Secher T., Ezhevsky S. A., Janot L., Steed P. M., O'Brien C., Eivazi A., Kung J., Nguyen D. H. T., Doberstein S. K., Erard F., Ryffel B., Szymkowski D. E., Dominant-negative inhibitors of soluble TNF attenuate experimental arthritis without suppressing innate immunity to infection. Journal of Immunology 2007 179 3 1872 1883 2-s2.0-34548657310
180. Black R. A., Rauch C. T., Kozlosky C. J., Peschon J. J., Slack J. L., Wolfson M. F., Castner B. J., Stocking K. L., Reddy P., Srinivasan S., Nelson N., Boiani N., Schooley K. A., Gerhart M., Davis R., Fitzner J. N., Johnson R. S., Paxton R. J., March C. J., Cerretti D. P., A metalloproteinase disintegrin that releases tumour-necrosis factor- from cells. Nature 1997 385 6618 729 733 2-s2.0-8044257704 10.1038/385729a0 (Pubitemid 27098094)
181. Chen X., Oppenheim J. J., Contrasting effects of TNF and anti-TNF on the activation of effector T cells and regulatory T cells in autoimmunity. FEBS Letters 2011 585 23 3611 3618 2-s2.0-80052680230 10.1016/j.febslet.2011.04.025
182. Grell M., Douni E., Wajant H., Lohden M., Clauss M., Maxeiner B., Georgopoulos S., Lesslauer W., Kollias G., Pfizenmaier K., Scheurich P. S., The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor. Cell 1995 83 5 793 802 2-s2.0-0028866022
183. Chen G., Goeddel D. V., TNF-R1 signaling: a beautiful pathway. Science 2002 296 5573 1634 1635 2-s2.0-0037204948 10.1126/science.1071924 (Pubitemid 34579145)
184. Cuenca J., Cuchacovich M., Pérez C., Ferreira L., Aquirre A., Schiattino I., Soto L., Cruzat A., Salazar-Onfray F., Aguillón J. C., The -308 polymorphism in the tumour necrosis factor (TNF) gene promoter region and ex vivo lipopolysaccharide-induced TNF expression and cytotoxic activity in Chilean patients with rheumatoid arthritis. Rheumatology 2003 42 2 308 313 2-s2.0-0345700858 10.1093/rheumatology/keg092 (Pubitemid 36305619)
185. Chen X., Wu X., Zhou Q., Howard O. M., Netea M. G., Oppenheim J. J., TNFR2 is critical for the stabilization of the CD4+Foxp3+ regulatory T. cell phenotype in the inflammatory environment. Journal of Immunology 2013 190 3 1076 1084 10.4049/jimmunol.1202659
186. Kleijwegt F. S., Laban S., Duinkerken G., Joosten A. M., Zaldumbide A., Nikolic T., Roep B. O., Critical role for TNF in the induction of human antigen-specific regulatory T cells by tolerogenic dendritic cells. Journal of Immunology 2010 185 3 1412 1418 2-s2.0-77956395771 10.4049/jimmunol.1000560
187. Corona-Sanchez E. G., Muñoz-Valle J. F., Gonzalez-Lopez L., Sanchez-Hernandez J. D., Vazquez-Del Mercado M., Ontiveros-Mercado H., Huerta M., Trujillo X., Rocha-Muñoz A. D., Celis A., Ortega-Flores R., Gamez-Nava J. I., -383 A/C tumor necrosis factor receptor 1 polymorphism and ankylosing spondylitis in Mexicans: a preliminary study. Rheumatology International 2012 32 8 2565 2568 2-s2.0-79960562561 10.1007/s00296-011-1997-5